Multimorbidity of intestinal cancer (IC), type 2 diabetes (T2D) and obesity is a posh set of ailments, affected by environmental and genetic threat components. High-fat diet (HFD) and oral bacterial infection play essential roles in the etiology of these ailments by way of irritation and numerous organic mechanisms. To research the complexity of this multimorbidity, we used the collaborative cross (CC) mouse genetics reference inhabitants. We aimed to research the multimorbidity of IC, T2D, and obesity using CC lines, measuring their responses to HFD and oral bacterial infection.
The research used 63 mice of each sexes generated from two CC lines (IL557 and IL711). For 12 weeks, experimental mice have been maintained on particular dietary regimes mixed with co-infection with oral micro organism Porphyromonas gingivalis and Fusobacterium nucleatum, whereas management teams weren’t contaminated. Body weight (BW) and outcomes of a intraperitoneal glucose tolerance check (IPGTT) have been recorded at the finish of 12 weeks, after which size and dimension of the intestines have been assessed for polyp counts. Polyp counts ranged between 2 and 10 per CC line.
The mixture of HFD and infection considerably diminished (P < .01) the colon polyp dimension of IL557 females to 2.5 cm2, in contrast to the different teams. Comparing BW achieve, IL557 males on HFD gained 18 g, whereas the females gained 10 g below the similar situations and confirmed the highest space below curve (AUC) values of 40 000-45 000 (min mg/dL) in the IPGTT. The outcomes present that mice from completely different genetic backgrounds reply in another way to a excessive fats diet and oral infection in phrases of polyp improvement and glucose tolerance, and this impact is gender associated.
Data have been extracted from the standardized Quality Data Collection Tool (QDACT). Adults with pancreatic cancer seen by a palliative care supplier have been included. Descriptive statistics have been used to describe demographic options, symptom prevalence and burden, in addition to assess affected person prognosis consciousness outlined by congruence or incongruence with supplier estimated prognosis.
Effect of Collaborative Review of Electronic Patient-Reported Outcomes for Shared Reporting in Breast Cancer Patients: Descriptive Comparative Study
Digital monitoring of treatment-related signs and self-reported affected person outcomes is essential for the high quality of care amongst cancer sufferers. As cellular gadgets are ubiquitous these days, the assortment of digital patient-reported outcomes (ePROs) is gaining momentum. So far, information are missing on the modalities that contribute to the amount and high quality of ePROs. The goal of our research was to examine the utilization of two variations of a subsequently employed cellular app for digital monitoring of PROs and to check our speculation {that a} shared evaluation of signs in patient-physician collaboration has an affect on the quantity of information entries.
The Consilium Care app engages cancer sufferers to standardize reporting of well-being and treatment-related signs in outpatient settings. For descriptive comparability of the utilization of two barely completely different app variations, information have been obtained from an early breast cancer trial (model 1 of the app, n=86) and an ongoing research together with sufferers with superior illness (model 2 of the app, n=106). In each app variations, sufferers and docs have been allowed to share the info from information entries throughout consultations. The numbers and varieties of symptom entries, satisfaction with each app variations, and sufferers’ perceived effects throughout consultations have been included for evaluation.
Symptom severity grading was carried out in accordance to the Common Terminology Criteria for Adverse Events (CTCAE) using a horizontal slider and was indicated in descriptive terminology in each apps, whereas a graphical show facilitated the illustration of symptom historical past charts. In whole, 192 sufferers electronically reported 11,437 information entries on well-being and 33,380 information entries on particular person signs. Overall, 628 (of 872 supposed) requested patient-doctor symptom critiques have been carried out in model 2 of the app.
Both the quantity of information entries per affected person and day for well-being (model 1 vs model 2: 0.three vs 1.0; P<.001) and signs (model 1 vs model 2: 1.three vs 1.9; P=.04) appeared considerably elevated in model 2 of the app. Overall satisfaction with each app variations was excessive, though model 2 of the app was perceived to be extra useful in basic. Version 2 of the app, nevertheless, randomly chosen signs that required an in depth and shared common patient-doctor evaluation in order to focus on the assortment and acceptable interpretation concerning consciousness and steerage for severity grading.
Dancing With Health: Quality of Life and Physical Improvements From an EU Collaborative Dance Programme With Women Following Breast Cancer Treatment
Women’s well being has obtained renewed consideration in the previous few years together with well being rehabilitation choices for girls affected by breast cancer. Dancing has usually been considered one enticing possibility for supporting girls’s well-being and well being, however analysis with girls recovering from breast cancer continues to be in its infancy. Dancing with Health is multi-site pilot research that aimed to consider a dance programme for girls in restoration from breast cancer throughout 5 European nations.
A standardized 32 h dance protocol launched a variety of Latin American dances offered inside a sports activities and train framework with influences from dance motion remedy. Fifty-four girls (M age 53.51; SD 7.99) participated in the research who had a breast cancer prognosis <three years, chemotherapy >6 weeks, no indication of metastasis, or scheduled surgical procedure/chemotherapy/radiation remedy for the length of the intervention. Primary consequence information was collected for anthropometric and health measures subsequent to cancer-related high quality of life. T-tests and Wilcoxon signed ranked checks have been used to set up variations pre and publish intervention.
MIPT3 Antibody |
|||
| abx119584-50l | Abbexa | 50 µl | EUR 237.5 |
MIPT3 Antibody |
|||
| E11-13085C | EnoGene | 100μg | EUR 225 |
|
Description: Available in various conjugation types. |
|||
MIPT3 antibody |
|||
| MBS5300537-01mg | MyBiosource | 0.1mg | EUR 465 |
MIPT3 antibody |
|||
| MBS5300537-5x01mg | MyBiosource | 5x0.1mg | EUR 1945 |
MIPT3 Antibody |
|||
| MBS853423-01mg | MyBiosource | 0.1mg | EUR 305 |
MIPT3 Antibody |
|||
| MBS853423-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
MIPT3 Antibody |
|||
| MBS853423-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
MIPT3 Antibody |
|||
| MBS853423-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
MIPT3 Antibody |
|||
| MBS853423-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
MIPT3 Antibody |
|||
| MBS9505833-005mL | MyBiosource | 0.05mL | EUR 285 |
MIPT3 Antibody |
|||
| MBS9505833-01mL | MyBiosource | 0.1mL | EUR 385 |
MIPT3 Antibody |
|||
| MBS9505833-5x01mL | MyBiosource | 5x0.1mL | EUR 1590 |
MIPT3 antibody |
|||
| 70R-33832 | Fitzgerald Industries International | 100 ug | Ask for price |
MIP-T3 Antibody |
|||
| C13085-100ul | Assay Biotech | 100μl | EUR 217 |
|
Description: MIP-T3 Rabbit Polyclonal Antibody |
|||
MIP-T3 Antibody |
|||
| C13085-50ul | Assay Biotech | 50μl | EUR 143.5 |
|
Description: MIP-T3 Rabbit Polyclonal Antibody |
|||
MIP-T3 Polyclonal Antibody |
|||
| ABP54468-003ml | Abbkine | 0.03ml | EUR 189.6 |
|
Description: A polyclonal antibody for detection of MIP-T3 from Human. This MIP-T3 antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human MIP-T3 at AA rangle: 190-270 |
|||
MIP-T3 Polyclonal Antibody |
|||
| ABP54468-01ml | Abbkine | 0.1ml | EUR 346.8 |
|
Description: A polyclonal antibody for detection of MIP-T3 from Human. This MIP-T3 antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human MIP-T3 at AA rangle: 190-270 |
|||
MIP-T3 Polyclonal Antibody |
|||
| ABP54468-02ml | Abbkine | 0.2ml | EUR 496.8 |
|
Description: A polyclonal antibody for detection of MIP-T3 from Human. This MIP-T3 antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human MIP-T3 at AA rangle: 190-270 |
|||
MIP-T3 Polyclonal Antibody |
|||
| BT-AP05430-100ul | Jiaxing Korain Biotech Ltd (BT Labs) | 100ul | Ask for price |
|
Description: Play an inhibitory role on IL13 signaling by binding to IL13RA1. Involved in suppression of IL13-induced STAT6 phosphorylation, transcriptional activity and DNA-binding. Recruits TRAF3 and DISC1 to the microtubules. |
|||
MIP-T3 Polyclonal Antibody |
|||
| BT-AP05430-20ul | Jiaxing Korain Biotech Ltd (BT Labs) | 20ul | Ask for price |
|
Description: Play an inhibitory role on IL13 signaling by binding to IL13RA1. Involved in suppression of IL13-induced STAT6 phosphorylation, transcriptional activity and DNA-binding. Recruits TRAF3 and DISC1 to the microtubules. |
|||
MIP-T3 Polyclonal Antibody |
|||
| BT-AP05430-50ul | Jiaxing Korain Biotech Ltd (BT Labs) | 50ul | Ask for price |
|
Description: Play an inhibitory role on IL13 signaling by binding to IL13RA1. Involved in suppression of IL13-induced STAT6 phosphorylation, transcriptional activity and DNA-binding. Recruits TRAF3 and DISC1 to the microtubules. |
|||
MIP-T3 Polyclonal Antibody |
|||
| JOT-AP05430-100ul | Jotbody | 100ul | EUR 220 |
|
Description: Human |
|||
MIP-T3 Polyclonal Antibody |
|||
| JOT-AP05430-50ul | Jotbody | 50ul | EUR 144 |
|
Description: Human |
|||
MIP-T3 Polyclonal Antibody |
|||
| E44H05276 | EnoGene | 100ul | EUR 255 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
MIP-T3 Polyclonal Antibody |
|||
| E20-72768 | EnoGene | 100ug | EUR 225 |
|
Description: Available in various conjugation types. |
|||
MIP-T3 Polyclonal Antibody |
|||
| MBS8523749-01mg | MyBiosource | 0.1mg | EUR 305 |
MIP-T3 Polyclonal Antibody |
|||
| MBS8523749-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
MIP-T3 Polyclonal Antibody |
|||
| MBS8523749-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
MIP-T3 Polyclonal Antibody |
|||
| MBS8523749-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
MIP-T3 Polyclonal Antibody |
|||
| MBS8523749-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
MIP-T3 Polyclonal Antibody |
|||
| UB-GEN-3875 | UpingBio | 100 ul | EUR 200 |
Rapid Human Antibody Isotyping Kit, 5pk |
|||
| 113101 | Antibody Research Corporation | 5 PKS | Ask for price |
MIP-T3 Rabbit Polyclonal Antibody |
|||
| ES5467-100ul | ELK Biotech | 100ul | EUR 124 |
|
Description: IHC, IF, ELISA |
|||
MIP-T3 Rabbit Polyclonal Antibody |
|||
| ES5467-50ul | ELK Biotech | 50ul | EUR 74 |
|
Description: IHC, IF, ELISA |
|||
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) |
|||
| MBS643331-02mL | MyBiosource | 0.2mL | EUR 695 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) |
|||
| MBS643331-5x02mL | MyBiosource | 5x0.2mL | EUR 2975 |
Anti-MIPT3 TRAF3IP1 Antibody |
|||
| A08944 | BosterBio | 100ul | EUR 335 |
|
Description: Boster Bio Anti-MIPT3 TRAF3IP1 Antibody (Catalog# A08944). Tested in WB, IHC-P, IF, ICC, ELISA applications. This antibody reacts with Human, Rat, Mouse. |
|||
Anti Human Alpha 1Anti Human Chymotrypsin Pab |
|||
| 111444 | Antibody Research Corporation | 100 µg | Ask for price |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (AP) |
|||
| MBS6357857-02mL | MyBiosource | 0.2mL | EUR 980 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (AP) |
|||
| MBS6357857-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (PE) |
|||
| MBS6357867-02mL | MyBiosource | 0.2mL | EUR 980 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (PE) |
|||
| MBS6357867-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (APC) |
|||
| MBS6357858-02mL | MyBiosource | 0.2mL | EUR 980 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (APC) |
|||
| MBS6357858-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (Biotin) |
|||
| MBS6357859-02mL | MyBiosource | 0.2mL | EUR 980 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (Biotin) |
|||
| MBS6357859-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (FITC) |
|||
| MBS6357860-02mL | MyBiosource | 0.2mL | EUR 980 |
TRAF3IP1, ID (TRAF3IP1, MIPT3, TRAF3-interacting protein 1, Interleukin-13 receptor alpha 1-binding protein 1, Microtubule-interacting protein associated with TRAF3) (FITC) |
|||
| MBS6357860-5x02mL | MyBiosource | 5x0.2mL | EUR 4250 |
Anti Human LH Pab |
|||
| 111053 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human C3 Mab |
|||
| 111163 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human C5 Mab |
|||
| 111164 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human TF Pab |
|||
| 111263 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human LYN Mab |
|||
| 831082 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human FYN Mab |
|||
| 831084 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PSA Pab |
|||
| 165726 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD2 Mab |
|||
| 272062 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human C4a Mab |
|||
| 272103 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human FSH Mab |
|||
| 272142 | Antibody Research Corporation | 1 mg | Ask for price |
Anti Human FSH Pab |
|||
| 272143 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CPD Pab |
|||
| 272458 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human IgE Mab |
|||
| 121026 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PAI Pab |
|||
| 164045 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Tau Mab |
|||
| 164070 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human BNP Pab |
|||
| 165460 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human C4d Pab |
|||
| 165468 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD2 Pab |
|||
| 165486 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD7 Pab |
|||
| 165491 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CEA Pab |
|||
| 165493 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CK7 Pab |
|||
| 165510 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human EGF Pab |
|||
| 165555 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Tau Pab |
|||
| 111112 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human p53 Pab |
|||
| 111304 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human FLK Pab |
|||
| 111462 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human C4b Pab |
|||
| 111488 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD8 Pab |
|||
| 111494 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Mu2 Pab |
|||
| 111499 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human ROS Pab |
|||
| 111519 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human FGR Pab |
|||
| 111676 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human JUN Pab |
|||
| 111686 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human LYN Pab |
|||
| 111689 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human MET Pab |
|||
| 111693 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human MYC Pab |
|||
| 111694 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human REL Pab |
|||
| 111712 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CA 15-3 Pab |
|||
| 165469 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CA 19-9 Pab |
|||
| 165470 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CA 72-4 Pab |
|||
| 165471 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PAK1 Mab |
|||
| 831081 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CDK2 Mab |
|||
| 831085 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human LDH1 Pab |
|||
| 165614 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Muc2 Pab |
|||
| 165669 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Muc4 Pab |
|||
| 165670 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human NGFR Pab |
|||
| 165682 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PAX5 Pab |
|||
| 165709 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PAX8 Pab |
|||
| 165710 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PTEN Pab |
|||
| 165729 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human TLR2 Pab |
|||
| 165782 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human TLR9 Pab |
|||
| 165783 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human GCSF Mab |
|||
| 181038 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human GRK5 Mab |
|||
| 272242 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human KLK8 Pab |
|||
| 272446 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human KLK8 Mab |
|||
| 272447 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD47 Mab |
|||
| 161740 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Flk1 Pab |
|||
| 162168 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human MMP7 Pab |
|||
| 162385 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human FSHR Pab |
|||
| 164038 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Muc1 Pab |
|||
| 164043 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human UGRP Pab |
|||
| 164048 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human TIM1 Pab |
|||
| 164072 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human FABP Pab |
|||
| 164279 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human GP73 Pab |
|||
| 164281 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CASR Mab |
|||
| 164515 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD77 Pab |
|||
| 164516 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human RHCT Mab |
|||
| 165185 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Tim3 Pab |
|||
| 165188 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human ASIC Mab |
|||
| 165379 | Antibody Research Corporation | 1 mg | Ask for price |
Anti Human ASIC Pab |
|||
| 165380 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD6 [2G11] |
|||
| 165383 | Antibody Research Corporation | 1 mg | Ask for price |
Anti Human Bcl2 Pab |
|||
| 165448 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human BCMA Pab |
|||
| 165449 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human BMP9 Pab |
|||
| 165459 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Braf Pab |
|||
| 165463 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD15 Pab |
|||
| 165485 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD38 Pab |
|||
| 165487 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD47, Pab |
|||
| 165488 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD54 Pab |
|||
| 165489 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD57 Pab |
|||
| 165490 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CK20 Pab |
|||
| 165509 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CKMM Pab |
|||
| 165511 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human EGFR Pab |
|||
| 165556 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD38 Mab |
|||
| 100117 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD22 Mab |
|||
| 100161 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human GCSF Pab |
|||
| 111054 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human IGF1 Pab |
|||
| 111091 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human NKX2.2 Pab |
|||
| 111171 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CBX4 Pab |
|||
| 111235 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD20 Pab |
|||
| 111237 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD34 Pab |
|||
| 111290 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD44 Pab |
|||
| 111292 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD45 Pab |
|||
| 111293 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human GFAP Pab |
|||
| 111298 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Toso Mab |
|||
| 111313 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PICP Pab |
|||
| 111508 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PINP Pab |
|||
| 111509 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human IL35 Pab |
|||
| 111516 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human GDF9 Pab |
|||
| 111520 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CD90 Mab |
|||
| 111529 | Antibody Research Corporation | 1 mg | Ask for price |
Anti Human Cul1 Pab |
|||
| 111534 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human Cul3 Pab |
|||
| 111535 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human GLP1 Pab |
|||
| 111544 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human TFPI Mab |
|||
| 111563 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human SUMO Mab |
|||
| 111588 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human TFPI Pab |
|||
| 111636 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CDH1 Pab |
|||
| 111663 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human IL1B Pab |
|||
| 111683 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human LMNA Pab |
|||
| 111687 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human MCL1 Pab |
|||
| 111692 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PCNA Pab |
|||
| 111702 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human PTK2 Pab |
|||
| 111710 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human RELA Pab |
|||
| 111713 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human RXRA Pab |
|||
| 111714 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human SOX2 Pab |
|||
| 111715 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human TP53 Pab |
|||
| 111720 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human CSF1 Pab |
|||
| 111783 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human TLR4 Pab |
|||
| 111784 | Antibody Research Corporation | 100 µg | Ask for price |
Anti Human GHRP Pab |
|||
| 112002 | Antibody Research Corporation | 100 µg | Ask for price |
Cohen’s d was additionally calculated to decide the impact dimension of the intervention. Statistically important adjustments have been discovered for: (i) weight, proper and left forearm circumference and hip; (ii) 6 min strolling, proper and left handgrip, sit-to-stand and sit-and-reach; (iii) the EORTC-QLQ C30 abstract rating in addition to the subscales of emotional and social functioning and signs. In all instances the route of change was constructive, whereas Cohen’s d calculated confirmed that the impact of the intervention for these parameters ranged from intermediate to giant.